ArticleScience advances2022
Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 111 citations in OpenAlex.
- Growth plate cartilage-targeting nanoparticles for pharmacological treatment of hypochondroplasia.Bioactive materials · 2026Article
- A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury.Bioactive materials · 2026Article
- Hypothalamic wars: the last nanodelivery.Reviews in endocrine & metabolic disorders · 2026Review
- Soft cell-derived hybrid microparticles with platelet decoys for enhanced cancer chemotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Biomimetic nanovesicles and nanotechnology for oral and maxillofacial diseases.Discover nano · 2026Review
- Advances in isolation and detection technologies and immunotherapy applications of circulating tumor cells (Review).Oncology reports · 2026Review
- Antibody-Targeted Artificial T Cell and Natural Killer Cell Derived Vesicles for Cancer Immunotherapy.Journal of extracellular vesicles · 2026Article
- Preclinical assessment of genetically modified exosomes for colorectal cancer immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Spatiotemporal-adaptive nanotherapeutics promote post-injury regeneration in ageing through metabolic modulation.Nature nanotechnology · 2025Article
- Cryogel-Based Dendritic Cell Immunotherapy for Post-Surgical Breast Cancer Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Stimuli-Responsive, Cell-Mediated Drug Delivery Systems: Engineering Smart Cellular Vehicles for Precision Therapeutics.Pharmaceutics · 2025Review
- TMTP1-modified polymeric micelles for the inhibition of ovarian cancer metastasis and recurrence through enhanced photothermal-immunotherapy.Materials today. Bio · 2025Article
- NIR-responsive cisplatin nanoparticles for synergistic chemo-photothermal therapy of oral squamous cell carcinoma.RSC advances · 2025Article
- Unleashing the Potential of Metal Ions in cGAS-STING Activation: Advancing Nanomaterial-Based Tumor Immunotherapy.ACS omega · 2025Review
- Synthetic Biology-Based Engineering Cells for Drug Delivery.Exploration (Beijing, China) · 2025Review
- Cell membrane-derived nanovesicles as extracellular vesicle-mimetics in wound healing.Materials today. Bio · 2025Review
- Bioengineered therapeutic systems for improving antitumor immunity.National science review · 2025Review
- Application of cell-derived vesicle-based biomimetic drug delivery system in tumor therapy.Frontiers in pharmacology · 2025Review
- Biomimetic nanoparticles with red blood cell membranes for enhanced photothermal and immunotherapy for tumors.RSC advances · 2024Article
- Nanotechnology Applications in Breast Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer recurrence and metastasis are still common causes of postsurgery death in patients with solid tumors, suggesting that additional consolidation therapeutic strategies are necessary. We have previously found that oxaliplatin (OXA) treatment causes further up-regulation of CD155, which is abundantly expressed in tumors for resulting in increased sensitivity of cancer to anti-CD155 therapy. Here, we report O-TPNVs, which are TIGIT-expressing cell membrane and platelet cell membrane fusion nanovesicles (TPNVs) loaded with OXA. Platelet-derived membrane components enable O-TPNVs to target postsurgery wounds and interact with circulating tumor cells (CTCs). OXA directly kills residual tumor cells and CTCs, induces immunogenic cell death, and activates the immune system. TPNVs bind to CD155 on tumor cells, block the CD155/TIGIT pathway, and restore CD8
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.